No­vo Nordisk to boost oral GLP-1 man­u­fac­tur­ing via $92.5M buy for Alk­er­mes’ Ire­land fa­cil­i­ty

No­vo Nordisk will buy Alk­er­mes’ tablet­ing fa­cil­i­ty in Athlone, Ire­land, for $92.5 mil­lion in cash to man­u­fac­ture one of its block­buster GLP-1 drugs — Ry­bel­sus — as well as fu­ture prod­ucts, ac­cord­ing to a No­vo spokesper­son.

Alk­er­mes sell­ing its fa­cil­i­ty is al­so a part of its plans to be­come a pure-play neu­ro­science com­pa­ny. Last month, Alk­er­mes’ on­col­o­gy unit spun out to be­come Mur­al On­col­o­gy, an in­de­pen­dent, pub­licly-list­ed $MU­RA com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER